

RESEARCH ARTICLE

# Efficiency of protein synthesis inhibition depends on tRNA and codon compositions

Sophia Rudolf \*

Theory and Bio-Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany

\* [sophia.rudorf@mpikg.mpg.de](mailto:sophia.rudorf@mpikg.mpg.de)



## Abstract

Regulation and maintenance of protein synthesis are vital to all organisms and are thus key targets of attack and defense at the cellular level. Here, we mathematically analyze protein synthesis for its sensitivity to the inhibition of elongation factor EF-Tu and/or ribosomes in dependence of the system's tRNA and codon compositions. We find that protein synthesis reacts ultrasensitively to a decrease in the elongation factor's concentration for systems with an imbalance between codon usages and tRNA concentrations. For well-balanced tRNA/codon compositions, protein synthesis is impeded more effectively by the inhibition of ribosomes instead of EF-Tu. Our predictions are supported by re-evaluated experimental data as well as by independent computer simulations. Not only does the described ultrasensitivity render EF-Tu a distinguished target of protein synthesis inhibiting antibiotics. It may also enable persister cell formation mediated by toxin-antitoxin systems. The strong impact of the tRNA/codon composition provides a basis for tissue-specificities of disorders caused by mutations of human mitochondrial EF-Tu as well as for the potential use of EF-Tu targeting drugs for tissue-specific treatments.

## OPEN ACCESS

**Citation:** Rudolf S (2019) Efficiency of protein synthesis inhibition depends on tRNA and codon compositions. *PLoS Comput Biol* 15(8): e1006979. <https://doi.org/10.1371/journal.pcbi.1006979>

**Editor:** Shi-Jie Chen, University of Missouri, UNITED STATES

**Received:** March 25, 2019

**Accepted:** July 15, 2019

**Published:** August 1, 2019

**Copyright:** © 2019 Sophia Rudolf. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript and its Supporting Information files.

**Funding:** SR was supported by the German Science Foundation (Deutsche Forschungsgemeinschaft) via Research Unit FOR 1805: <http://gepris.dfg.de/gepris/projekt/207100805>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Author summary

We predict and analyze the response of differently composed protein synthesis systems to the inhibition of elongation factor EF-Tu and/or ribosomes. The study reveals a strong interdependency of a protein synthesis system's composition and its susceptibility to inhibition. This interdependency defines a generic mechanism that provides a common basis for a variety of seemingly unrelated phenomena including, for example, persister cell formation and tissue-specificity of certain mitochondrial diseases. The described mechanism applies to simple artificial translation systems as well as to complex protein synthesis in vivo.

## Introduction

Ribosomes and elongation factors EF-Tu are the most important targets of antibiotics inhibiting bacterial protein synthesis because of the crucial roles they play in this vital process [1, 2]. Ribosomes are molecular machines that use the genetic information stored in messenger RNAs (mRNAs) to synthesize proteins. Elongation factors EF-Tu bind aminoacylated tRNAs


and guanosine-5'-triphosphate (GTP) molecules to form ternary complexes, which deliver the aminoacyl-tRNAs to the ribosomes, see Fig 1. A major fraction of antibiotics that interfere with protein synthesis is directed against the ribosome [3, 4], whereas a minor fraction is directed against EF-Tu [5]. In addition to compounds targeting either the ribosome or EF-Tu, antibiotics of the kirromycin and enacyloxin IIa families inhibit ribosomes and EF-Tu simultaneously by stalling the ternary complex on the ribosome [6–9], see Table 1. Fig 1 gives a schematic overview over these three distinct inhibition pathways.

Although EF-Tu and the ribosome are both fundamental for bacterial mRNA translation, they are very distinct in terms of, e.g., function, abundance, structure, or interactions with other components of the bacterial protein synthesis machinery. Therefore, it is not obvious under which conditions which of the three inhibition pathways depicted in Fig 1 is the most efficient one, i.e., under which conditions EF-Tu is a more suitable target than the ribosome for down-regulation of bacterial protein synthesis. To address this question, it is necessary to understand how sensitively protein synthesis responds to a decline in the availability of EF-Tu and under which conditions it reacts more sensitively to the loss of functional EF-Tu than to the loss of functional ribosomes.

Moreover, the sensitivity of protein synthesis to EF-Tu inhibition is not only an important aspect of drug effectiveness. In fact, it might also provide a further and so-far undescribed basis for an anti-drug defense mechanism called bacterial persistence, which is applied by bacteria when they suppress their own growth to defend themselves against antibiotic attacks.

Bacterial infections can relapse or become chronic after antibiotic treatments. One major reason for this failure of antibiotics is bacterial persistence [10]. Persistent bacteria are able to tolerate exposure to antibiotics as well as other negative influences from the environment. In contrast to antibiotic resistant cells, *persisters* are genetically identical to drug-sensitive individuals of the same population. The persistence arises from stochastic phenotypic transitions resulting in strongly reduced growth rates [11]. The switching between a fast-growing and a dormant cell state can be mediated by different toxin-antitoxin systems, as recently reviewed in [12]. A toxin-antitoxin system consists of two components, a growth-inhibiting toxin and an antagonistic antitoxin. When the antitoxin gets degraded, the toxin can fully develop its growth-arresting effect, i.e., persistence is induced and the cell is protected from the adverse effects of antibiotics. Toxin-antitoxin mediated phenotypic transitions from the fast-growing to the dormant phenotype and *vice versa* were found to be caused by stochastic fluctuations of the abundance of free toxin above and below a certain threshold [13], where the switching rates need to be fast enough. If the switching rates are too low, the fraction of persister cells is too small to guarantee survival of the population under stress conditions. In addition, the persisters die before regaining full growth because the continuous impact of the toxin leads to cell death [14]. Recently, the *phd/doc* toxin-antitoxin system was discussed in the context of persister cell formation [15]. The antitoxin Phd inactivates the toxin Doc that in turn was found to inhibit elongation factor EF-Tu by phosphorylating it at position Thr382 [16, 17]. Phosphorylation of EF-Tu at position Thr382 suppresses ternary complex formation and, thus, protein synthesis [17, 18]. Therefore, in principle the *phd/doc* toxin-antitoxin system can facilitate transitions between a persistent phenotype with strongly reduced protein synthesis and a fast-growing phenotype with maximal protein synthesis.

EF-Tu is one of the most abundant proteins in bacteria to compensate for limited diffusion caused by molecular crowding [19]. It is unlikely that a major fraction of the EF-Tu molecules gets phosphorylated at the same time. This brings up the question: Does bacterial protein synthesis respond indeed in a highly sensitive manner to EF-Tu inhibition, rendering Doc an efficient toxin despite the vast cellular abundance of its target and making *phd/doc*-mediated phenotypic transitions fast enough to enable persister formation and survival?



**Fig 1. Ribosome and EF-Tu as targets for protein synthesis inhibition.** After a tRNA (gray sphere) is released from a ribosome (gray dome), it binds to an aminoacyl-tRNA synthetase (violet box) that recharges the tRNA with its cognate amino acid (green sphere). Under physiological conditions, the recharged tRNA binds to elongation factor EF-Tu (blue sphere) to form a ternary complex that delivers its amino acid to a translating ribosome. If EF-Tu gets inhibited, e.g., by an antibiotic or toxin, it is no longer able to bind aminoacylated tRNAs (A). Alternatively, protein synthesis and, thus, cellular growth can be impeded through ribosome inhibition (B) or via simultaneous inhibition of ribosomes and EF-Tu (C). See Table 1 for more details on the different inhibition pathways.

<https://doi.org/10.1371/journal.pcbi.1006979.g001>

To assess the sensitivity of protein synthesis to EF-Tu inhibition and answer these questions, we apply a previously published computational framework of *in-vivo*-like bacterial protein synthesis [27, 28] that was recently further validated by experiment [29]. In particular, we study the effect of variations of the EF-Tu concentration on the translational state of a cell. We compare the behavior of our computational *in-vivo*-like translation system both to re-evaluated published experimental data for different *E. coli* strains [30] and to highly simplified artificial bacterial translation systems based on only one or two codons and their cognate tRNAs. We conclude that imbalances between tRNA abundances and codon usages lead to an ultra-sensitive dependence of cellular protein synthesis on EF-Tu concentration. We confirm these findings by computer simulations of the *in-vitro* synthesis of fMetLysHis tripeptides using the “PURE system simulator” [31] and compare the effects of EF-Tu and ribosome inhibition on the synthesis rate.

## Results

Translating ribosomes proceed at an average or overall protein synthesis rate that is cell-type- and growth-condition-specific. We applied our computational framework of protein synthesis published in [27, 28] for *E. coli* growing at a specific rate of 2.5 h<sup>-1</sup> under physiological conditions, and calculated the overall elongation rate for different concentrations of EF-Tu. We

**Table 1. Some examples for reported mechanisms of translation inhibition targeting the ribosome and/or EF-Tu as illustrated in Fig 1, with no claim to completeness.**

Fig 1	Target	Mechanism	Reference
A	EF-Tu	Phosphorylation by toxin Doc suppresses ternary complex formation	[16–18]
		Antibiotics pulvomycin and GE2270 A sterically hinder ternary complex formation	[9, 20–23] and refs. therein
B	Ribosome	Inhibition by a multitude of antibiotics and antimicrobial peptides through divers mechanisms	[4, 24] and refs. therein
C	Ribosome and EF-Tu	Phosphorylation by Ser/Thr kinase YabT stabilizes EF-Tu on the ribosome	[25]
		Antibiotics kirromycin and enacyloxin IIa block the release of EF-Tu from the ribosome	[6–9, 26] and refs. therein

<https://doi.org/10.1371/journal.pcbi.1006979.t001>

found that even a minor decrease in the abundance of EF-Tu has a strong inhibiting effect on protein synthesis, see Fig 2A). Reducing the amount of EF-Tu by about 15% leads to a decrease in the overall elongation rate by half of its physiological value. Inhibiting about 20% of all EF-Tu molecules is already sufficient to cause an almost complete suppression of protein synthesis. For comparison, we re-evaluated and re-scaled published experimental data by van der Meide [30] as described in S1 Text. Most of the examined *E. coli* strains with mutated *tufA* and/or *tufB* genes coding for EF-Tu show indeed a dependence of the overall elongation rate on EF-Tu that is similar to the dependence predicted by our computational framework, see Fig 2B). This EF-Tu dependence is strain-specific: For example, the overall elongation rate increases slightly more smoothly with the EF-Tu concentration for the strain LB2021 with EF-Tu symbol “A<sub>R</sub>B<sub>O</sub>” than for the other strains. In the following sections, we show that the strain-specificity of the response to a decrease in EF-Tu availability can be explained by differences in the tRNA/codon compositions of the strains.


*E. coli* has a complex decoding system with 61 sense codons and 43 tRNAs that are either cognate, near-cognate, or non-cognate to each of the codons. This complexity, which is fully captured by our computational *in-vivo*-like translation system [28], makes it difficult to study the molecular origin of the ultrasensitive dependence of protein synthesis on EF-Tu concentration. To get additional insight, we greatly simplify our computational protein synthesis framework and examine two artificial translation systems with highly reduced sets of codons and tRNAs, instead.

### One-codon-one-tRNA (1C-1T) translation system is not ultrasensitive to EF-Tu concentration

The simplest translation system consists of one codon and one tRNA that is cognate to the codon. Experimentally, such a one-codon-one-tRNA (1C-1T) model is realized by a cell-free (*in-vitro*) expression system containing for example only poly-U mRNA and Phe-tRNA<sup>Phe</sup>. In S1 Text, all details on the system of equations describing the 1C-1T model can be found. For such a 1C-1T translation system, the dependence of the overall elongation rate on the EF-Tu concentration follows a Michaelis-Menten-like behavior: At first, the overall elongation rate increases linearly with increasing EF-Tu concentration and then levels off once it has reached a certain saturation value, see Fig 3A). We conclude that a 1C-1T translation system is not ultrasensitive to the abundance of EF-Tu. Instead, at lower values the overall elongation rate is approximately proportional to the EF-Tu concentration; in contrast to *in-vivo* translation, which requires a substantial amount of EF-Tu for significant protein synthesis, see Fig 2.

### Ultrasensitivity to EF-Tu concentration is caused by imbalances between codon usage and tRNA concentrations

Because 1C-1T translation cannot explain the efficient regulation of protein synthesis via EF-Tu as observed in *E. coli*, we slightly increase the complexity of our computational framework by a second codon and a second tRNA, thereby introducing a two-codon-two-tRNA (2C-2T) translation model. Both tRNAs are assumed to be cognate to one of the two codons, but near-cognate to the other: in particular, tRNA 1 is cognate to codon 1 and near-cognate to codon 2, and *vice versa*. Codons 1 and 2 appear with normalized codon usages  $p_1$  and  $p_2$ , respectively, with  $p_1 + p_2 = 1$ . The corresponding tRNAs 1 and 2 have molar concentrations  $X_1$  and  $X_2$ , respectively. As an example, a 2C-2T *in-vitro* translation system would consist of Phe-tRNA<sup>Phe</sup><sub>GAA</sub>, Cys-tRNA<sup>Cys</sup><sub>GCA</sub>, and mRNAs consisting only of UUC and UGC codons. The system of equations describing 2C-2T translation is given with all details in S1 Text. Because this system of equations has no explicit solution, we numerically solved it for the overall elongation



**Fig 2. Ultrasensitive dependence of the overall elongation rate on EF-Tu concentration in *E. coli*.** A) Theoretical predictions for *E. coli* growing at a specific growth rate of  $2.5 \text{ h}^{-1}$  with a physiological EF-Tu concentration of about  $250 \text{ } \mu\text{M}$  (blue dashed line) [32]. If the EF-Tu concentration is reduced by 15% (orange dashed line), the overall elongation rate strongly decreases by about 50%. When 20% of all EF-Tu molecules are inhibited (red dashed line), a critical EF-Tu concentration is reached, at which protein synthesis is almost completely suppressed. B) Experimental data from van der Meide (Fig. 3 in Ref. [30]), showing an ultrasensitive dependence of the overall elongation rate on EF-Tu for most of the studied *E. coli* strains. To facilitate comparison, data are rescaled as described in S1 Text and solid lines are drawn as a guide to the eye (no model fitting). Symbols represent different *E. coli* strains with mutated *tufA* and/or *tufB* genes coding for EF-Tu, see Table 2 in Ref. [30].

<https://doi.org/10.1371/journal.pcbi.1006979.g002>


rate as a function of the EF-Tu concentration. For perfectly balanced conditions with  $X_1/X_2 = p_1/p_2$ , where the relative abundance of the tRNAs matches the corresponding codon usages, 2C-2T translation is *not* ultrasensitive to the abundance of EF-Tu. In fact, the overall elongation rate has almost the same dependence on the concentration of EF-Tu as for the 1C-1T system, see Fig 3A). However, if the relative tRNA concentrations do not perfectly match the corresponding codon usages, the 2C-2T translation system responds in a much more complex way to variations of the EF-Tu availability: A regime of inhibited translation for small EF-Tu concentrations is followed by a relatively steep increase of the overall elongation rate, that finally saturates at larger EF-Tu concentrations, see Fig 3A). Thus, the ultrasensitivity to EF-Tu abundance found for *in-vivo* translation is also present in the imbalanced 2C-2T system, which renders the latter an appropriate model system to study the influence of EF-Tu abundance on translation.

### Onset of translation

In particular, we can apply the 2C-2T system to find out what determines the onset of translation, i.e., for which EF-Tu threshold concentration  $\mathcal{E}^*$  the overall elongation rate starts to increase. Fig 3A) shows that the position of the transition regime from strongly suppressed to physiological protein synthesis is shifted towards higher concentrations of EF-Tu for stronger mismatches of tRNA concentrations and codon usages. We discovered that the EF-Tu threshold concentration  $\mathcal{E}^*$  only depends on the total concentrations  $X_1$  and  $X_2$  of tRNA species 1 and 2 and the codon usages  $p_1$  and  $p_2$ . It does not depend on any other parameter of the translation system such as the many transition rates that govern the kinetics of protein synthesis. Instead, this dependence is described by the unexpectedly simple relation

$$\mathcal{E}^* = X_2 \left( \frac{X_1}{X_2} - \frac{p_1}{p_2} \right) = X_1 + X_2 - \frac{X_2}{p_2} \quad \text{for } \frac{X_1}{X_2} \geq \frac{p_1}{p_2} \quad \text{and } p_1 + p_2 = 1. \quad (1)$$

The EF-Tu threshold concentration for the parameter regime  $X_1/X_2 \leq p_1/p_2$  is obtained by swapping the indices 1 and 2 in Eq (1). A derivation of Eq (1) can be found in S1 Text. We also



**Fig 3. Ultrasensitivity in reduced translation systems.** A) Inhibition of EF-Tu generally leads to a decrease in the overall elongation rate. For the one-codon-one-tRNA (1C-1T) translation system (solid blue line), the overall elongation rate is proportional to the abundance of EF-Tu for low EF-Tu concentrations. The same holds for the 2C-2T translation system when codon usages  $p_i$  and tRNA concentrations  $X_i$  ( $i = 1, 2$ ) are perfectly balanced (dashed orange line;  $p_1/p_2 = X_1/X_2 = 1$ ). If the codon usages do not exactly match the relative tRNA concentrations, the overall elongation rate becomes ultrasensitive to the concentration of EF-Tu (green, red, and purple dashed lines;  $p_1/p_2 = 1$  and  $X_1/X_2$  as indicated). In all cases, the total tRNA concentration is  $X_1 + X_2 = 344 \mu\text{M}$ . Vertical solid black lines indicate EF-Tu threshold concentrations  $\mathcal{E}^* = 69 \mu\text{M}$ ,  $138 \mu\text{M}$  and  $206 \mu\text{M}$ , respectively, as given by Eq (1). B) Concentrations of free EF-Tu molecules (solid lines), free ternary complexes of the more abundant species 1 (dotted lines) and of the less abundant species 2 (dashed lines) as determined by the set of Eqs. (18)–(21) in S1 Text. In the low-concentration regime  $\mathcal{E} < \mathcal{E}^*$ , the free ternary complex concentration of the more abundant species 1 increases roughly linearly with  $\mathcal{E}$  whereas the concentration of the less abundant species 2 remains practically zero up to  $\mathcal{E}^*$  (see also S3 and S4 Figs). Same parameters and corresponding color code as in A). C) PURE system simulator [31]: Quasi-steady state overall elongation rate of *in-vitro* fMetLysHis tripeptide synthesis as a function of EF-Tu concentration for  $X_{\text{Lys}} + X_{\text{His}} = 3.44 \mu\text{M}$  and  $X_{\text{Lys}}/X_{\text{His}}$  as indicated, see text for details. Vertical solid black lines indicate EF-Tu threshold concentrations determined by Eq (1). D) Response of the *in-vitro* fMetLysHis tripeptide synthesis system to a sudden drop in EF-Tu concentration from  $5 \mu\text{M}$  to  $3 \mu\text{M}$  at 100s after start of reaction as predicted by the PURE system simulator for tRNA concentrations  $X_{\text{Lys}} + X_{\text{His}} = 3.44 \mu\text{M}$  and  $X_{\text{Lys}}/X_{\text{His}} = 8/2$ .

<https://doi.org/10.1371/journal.pcbi.1006979.g003>

confirmed this relation for the singular case in which the ribosome cannot bind any near-cognate tRNAs, see S5 Fig. We conclude that the threshold concentration is determined by an imbalance between tRNA concentrations and cognate codon usages and that this imbalance can be expressed in terms of the total tRNA concentration  $X_1 + X_2$  and by the ratio  $\frac{X_2}{p_2}$  of tRNA concentration to cognate codon usage for the less abundant tRNA species 2. The less abundant tRNA is hardly bound by EF-Tu to form ternary complexes if the EF-Tu concentration is below the threshold, see Fig 3B), while the concentration of the other ternary complex species remains at a high level. The competition of free aminoacylated tRNAs for free EF-Tu molecules causes the ultrasensitivity of systems with imbalanced tRNA/codon compositions: The oversupplied tRNA acts as a competitive inhibitor for the formation of ternary complexes containing the less abundant tRNA. The loss of one ternary complex species consequently causes a

quasi break-down of protein synthesis [33]. A similar phenomenon was observed by Elf et al. when they analyzed the charging levels of isoacceptor tRNAs under amino acid starvation [34]. Elf et al. found that the sensitivities of tRNA charging levels and of translation rates to amino acid starvation depend on codon usages and tRNA concentrations, which is in line with the findings presented here. A direct quantitative comparison of the work by Elf et al. to our results is not feasible because the former is a highly simplified model of translation that neglects ternary complex formation. Still, it is notable that the inhibition of EF-Tu, which acts on protein synthesis in a global manner, and the deprivation of individual amino acids, which affects translation locally at the corresponding codons, have common characteristics.

Translation in *E. coli* is of course much more complex than in the simple 2C-2T system. Surprisingly, Eq (1) still provides a very good estimate for the *in-vivo* EF-Tu threshold concentration  $\mathcal{E}^{*,\text{viv}}$  that marks the onset of translation in Fig 2A). Analyzing our computational *in-vivo*-like translation system [28], we found that for *E. coli* growing at a specific rate of  $2.5 \text{ h}^{-1}$  under physiological conditions, ternary complexes containing Lys-tRNA<sup>Lys</sup> are most strongly affected by a decrease in available EF-Tu. The total concentration  $X_{\text{all}}$  of all tRNAs is  $344 \mu\text{M}$ , the total concentration  $X_{\text{Lys}}$  of tRNA<sup>Lys</sup> is  $10.43 \mu\text{M}$ , and the combined codon usage  $p_{\text{Lys}}$  of its cognate codons AAA and AAG is 7.46% [28, 35]. Thus, if we replace  $X_1 + X_2$  in (1) by  $X_{\text{all}}$  and  $X_2/p_2$  by  $X_{\text{Lys}}/p_{\text{Lys}}$ , we obtain

$$\mathcal{E}^{*,\text{viv}} = X_{\text{all}} - \frac{X_{\text{Lys}}}{p_{\text{Lys}}} = 204 \mu\text{M}, \quad (2)$$

for the EF-Tu threshold concentration of *E. coli* which corresponds to about 80% of the physiological EF-Tu concentration and is in excellent agreement with the *in-vivo* EF-Tu threshold concentration predicted by our computational *in-vivo*-like translation system, see Fig 2A).

### Validation by the PURE system simulator

To test the predictions of our computational framework of protein synthesis by an independent method, we computed the effect of EF-Tu limitation on the rate of protein synthesis using the “PURE system simulator” developed and published by Matsuura and co-workers [31]. This software is a highly detailed and experimentally well-validated *in-silico* representation of the *E. coli*-based reconstituted *in-vitro* protein synthesis system called PURE [36]. We used a recent version of the PURE system simulator, which was kindly provided by Drs. Matsuura and Shimizu, to simulate the *in-vitro* synthesis of fMetLysHis tripeptides *via* translation of short mRNAs consisting of a lysine and a histidine codon enclosed by a start and a stop codon (AUGAAACACUAA). Simulation of fMetLysHis synthesis by the PURE system simulator represents an *in-silico* prediction of a 2C-2T *in-vitro* translation experiment. In the simulation, we varied the initial concentration of EF-Tu from 0 to  $5 \mu\text{M}$  and determined for each EF-Tu concentration the rate of tripeptide synthesis at the end of the simulation after 1000 s when the simulated PURE system has long reached a quasi-steady state peptide synthesis rate. Fig 3C) shows that the quasi-steady state peptide synthesis rate in the simulated PURE system is ultrasensitive to the concentration of EF-Tu if the tRNA concentrations do not perfectly match the codon usages. Again, the onset of translation is well-predicted by Eq (1). In addition, we used the PURE system simulator to study the time-dependent response of 2C-2T *in-vitro* translation to a sudden drop in EF-Tu concentration. We simulated the synthesis of fMetLysHis tripeptides for 100s after which the synthesis rate has just reached a quasi-steady state level, see Fig 3D). At 100s, the concentration of total EF-Tu was reduced and the simulation was continued until the peptide synthesis has reached a plateau again, see Methods for details.

Fig 3D) shows that the simulated PURE translation system quickly adjusts to the new quasi-steady state after EF-Tu reduction.

### Only if codon usages and tRNA concentrations are in balance, inhibition of EF-Tu in addition to ribosomes has no impact on peptide synthesis

We used the PURE system simulator to compare the effects of EF-Tu inhibition as discussed above with the response of fMetLysHis synthesis to ribosome inhibition and the simultaneous inhibition of ribosomes and EF-Tu. We found that, in contrast to an inhibition that affects only EF-Tu, the (additional) inhibition of ribosomes causes an increase in the simulated peptide synthesis rate of the remaining ribosomes, as long as the inhibition is not too strong and the tRNA concentrations are sufficiently similar, see Fig 4. This means that the remaining ribosomes proceed faster and that, to some extent, this increase in ribosomal speed can balance the loss of ribosomes, such that in the simulations the total rate of peptide synthesis remains approximately constant under mild inhibiting conditions. However, when the difference between the concentrations of tRNA<sup>Lys</sup> and tRNA<sup>His</sup> is large enough, the simulated fMetLysHis synthesis is dominated by the availability of EF-Tu and an additional inhibition of ribosomes has a negligible effect on the peptide synthesis rate, see Fig 4A).


## Discussion

Efficient delivery of aminoacylated tRNAs to translating ribosomes is crucial for protein synthesis. In bacteria, this process is governed by the elongation factor Tu (EF-Tu), which is one of the most abundant proteins. We applied our computational framework of protein synthesis [28] to investigate the influence of the availability of EF-Tu on the bacterial translation process.

Surprisingly, we found a very limited tolerance of the translation system to deviations from physiological EF-Tu concentrations. Even a slight decline in EF-Tu availability causes a strong decrease of the overall translational activity. In turn, when the EF-Tu concentration reaches a certain threshold value, protein synthesis is switched on and the overall translation rate rises from zero to a physiological value within a relatively narrow range of EF-Tu concentrations. This ultrasensitivity is universal because it applies to both complex translation systems like *E. coli* containing 61 sense codons and 43 different tRNA species as well as simple artificial systems with only two codons and two cognate tRNAs. The onset of translation is determined by the imbalances between codon usages and cognate tRNA abundances. The corresponding EF-Tu threshold concentration can be obtained from an unexpectedly simple expression, see Eq (1). Our theoretical predictions were confirmed by experimental data published by van der Meide, see Fig 2, as well as by independent computer simulations of an *in-vitro* translation system using the PURE system simulator [31].

The ultrasensitive dependence of protein synthesis on EF-Tu might also be related to an observation made by Škrčić et al. The authors knocked-down mitochondrial initiation factor IF-3, which facilitates translation initiation, as well as mt-EF-Tu in leukemia cells [37]. Silencing of mitochondrial EF-Tu, but not IF-3, inhibited mitochondrial protein synthesis, which emphasizes the high regulatory power of EF-Tu.

The toxin Doc from the *phd/doc* toxin-antitoxin system inhibits EF-Tu by phosphorylation [17, 18]. Our results show that it is not necessary to phosphorylate a major fraction of EF-Tu to achieve a strong suppression of protein synthesis and, thus, cell growth. Instead, in *E. coli* only 20% of all EF-Tu molecules need to get phosphorylated by Doc to essentially stop protein production, which explains why Doc is an efficient toxin despite the extremely high cellular abundance of its target. Furthermore, the ultrasensitive dependence of protein synthesis on



**Fig 4. PURE system simulator: Effects of ribosome (and EF-Tu) inhibition on the synthesis of fMetLysHis tripeptides.** When the simulated PURE system is depleted for ribosomes (solid lines), the total rate of peptide synthesis decreases (purple) but the synthesis rate per ribosome increases as long as the ribosomal concentration is not too low (black). In contrast, Fig 3C) shows that upon depletion of EF-Tu (i.e., for constant concentration of ribosomes), both the peptide synthesis rate in total and per ribosome decrease. When the concentrations of ribosomes and EF-Tu molecules are inhibited simultaneously by the same absolute amounts (diamonds, [EF-Tu] = [ribosomes]), EF-Tu inhibition has a stronger influence on peptide synthesis than ribosome inhibition (A, B) unless the tRNA concentrations are comparable (C, D). For each data point, translation was simulated until a quasi-steady state was reached. Simulations were performed and parameterized as described in the Methods, with a total tRNA concentration of  $X_{Lys} + X_{His} = 3.44 \mu\text{M}$  and concentration ratios  $X_{Lys}/X_{His}$  as indicated.

<https://doi.org/10.1371/journal.pcbi.1006979.g004>

EF-Tu concentration implies that the *phd/doc* toxin-antitoxin system is an efficient regulator of protein synthesis. Cell growth can be easily regained as soon as the antitoxin Phd inhibits Doc as only relatively few EF-Tu molecules need to be reactivated by dephosphorylation. Consequently, this toxin-antitoxin system may mediate fast transitions from rapidly-growing to dormant phenotypes and *vice versa*. These transitions enable the effective formation of persister cells that can resist antibiotic treatments.

In fact, depending on the specific site of modification, phosphorylation and other modifications of EF-Tu can impact protein synthesis in different ways. For example, in contrast to the toxin Doc, the Ser/Thr kinase YabT simultaneously inhibits both EF-Tu and ribosomes in *Bacillus subtilis* by stabilizing EF-Tu on translating ribosomes [25]. As a further example, Jakobsson et al. have shown that post-translational modifications of EF-Tu at the N-terminus and at residue Lys55 have an impact on protein synthesis rates [38]. Antibiotics directed against bacterial protein synthesis have a similar plurality in their modes of action and inhibit the ribosome and EF-Tu either individually or simultaneously in various ways, see Table 1 for examples. We found that the efficiencies of these different protein synthesis suppression pathways depend on the tRNA and codon compositions of the translation system. For balanced translation systems, for which the tRNA abundances roughly match the corresponding codon usages, inhibition of ribosomes rather than EF-Tu has a strong impact on the peptide synthesis

rate. On the contrary, a decrease in EF-Tu greatly impedes protein synthesis in imbalanced systems, where the additional inhibition of ribosomes has a negligible effect.

The ultrasensitive dependence of the overall elongation rate on the EF-Tu concentration is inherent in imbalanced translation systems but not in systems with a balanced tRNA/codon composition. This observation provides a possible explanation for the strain-specific correlation of EF-Tu abundance and growth rate in *E. coli* that is described in Ref. [30], see also Fig 2B).

Moreover, the mechanism studied in this work may help to understand the tissue-specificity of mitochondrial disorders caused by mutations of human mitochondrial EF-Tu (mt-EF-Tu). Valente et al. report that a mutation in mt-EF-Tu that leads to severe inhibition of translation in mitochondria of the central nervous system does not affect other tissues [39, 40]. This tissue-specificity might be related to differential mitochondrial mRNA and tRNA expression giving rise to differences in the mitochondrial tRNA/codon composition of the various tissues: Protein synthesis in mitochondria with less balanced tRNA/codon compositions should be more susceptible to a decrease in the availability of functional mt-EF-Tu. However, these speculative assumptions about mitochondrial protein synthesis need to be confirmed by quantitative analyses, which require the development of specialized translation models.

The theoretical predictions presented in this work could be tested for *in-vitro* protein synthesis with cell-free expression systems as well as for *in-vivo* translation using, for example, EF-Tu and ribosome inhibiting drugs. Our finding, that the efficiency of protein synthesis inhibition mediated by EF-Tu depends on the tRNA/codon composition, hints towards a potential use of EF-Tu targeting drugs for tissue- or pathogen-specific treatments. It thus may encourage further studies for the identification of novel compounds directed against EF-Tu [41].

## Methods

### Theoretical framework

We performed our analysis within the theoretical framework of translation developed in Refs. [27, 28] and briefly summarized in S1 Text. The framework incorporates a multitude of factors that influence the speed and fidelity of cellular protein synthesis. Important parameters are concentrations (of ribosomes, tRNAs, mRNAs, and elongation factors), as well as codon usages and predicted *in-vivo* biochemical rates (for tRNA charging by aminoacyl-tRNA synthetases, ternary complex formation, and ribosomal kinetics). Furthermore, cognate, near-cognate, and non-cognate relations of all tRNAs and codons are taken into account. To capture the stochastic nature of protein synthesis, translation elongation is described as a continuous-time Markov process. For the analysis of protein synthesis in *E. coli* as shown in Fig 2A), we applied our computational framework of *in-vivo*-like translation as published in Ref. [28] without any changes in parameters (except for EF-Tu concentration) nor reaction pathways and, thus, refer the reader to the original publication for details on the method. Adjustments made to the framework to model protein synthesis in simplified 1C-1T and 2C-2T translation systems are described in S1 Text, with all parameters assuming the values given in Ref. [28].

### PURE system simulator

For simulations with the “PURE system simulator” [31], all parameters, such as kinetic rates and concentrations, except for the initial concentrations of mRNAs, tRNAs and EF-Tu were used as provided by Matsuura et al. to maximize comparability with the experimental PURE system. The concentration of mRNA was set to 10  $\mu\text{M}$ , the total (summed) concentration of tRNA<sup>Lys</sup> and tRNA<sup>His</sup> to 3.44  $\mu\text{M}$ , and the concentrations of all other tRNAs were set to zero.

No further changes were made to the system. Translation rates were calculated by dividing for each point in time the increment in tripeptide amount by the corresponding increment in time. To simulate the impact of EF-Tu inhibition as a function of time, translation was simulated until the translation rate has reached a quasi-steady state level. At the indicated point in time, the concentrations of all species containing EF-Tu were reduced by a specific amount (fraction). To compensate unintended losses of EF-Tu binding partners, such as tRNAs or ribosomes, the concentrations of these affected species were increased by corresponding amounts. For example, if the concentration of ternary complexes containing EF-Tu and Lys-tRNA<sup>Lys</sup> was decreased by a certain amount, the concentration of Lys-tRNA<sup>Lys</sup> was increased by the same amount. The original PURE system simulator can be downloaded from the website of Matsuura et al.: <https://sites.google.com/view/puresimulator> [31].

## Supporting information

### S1 Text. Supporting information text.

(PDF)

**S1 Fig. Conversion of specific growth rate data into overall elongation rates.** A) Growth rates and EF-Tu concentrations from van der Meide et al. (axes of ordinates and co-ordinates were interchanged) for different *E. coli* strains, see Table 2 and Fig. 3 in Ref. [30]. B) Interpolation of data from Liang et al. [42] (diamonds, solid line) relating growth rate and overall elongation rate in *E. coli*. Colored dots indicate growth rates as measured in A).

(PDF)

**S2 Fig. Translation as a Markov process published in [28].** During translation of a codon  $c$ , the ribosome attains different states ( $c|i$ ). Starting in state ( $c|0$ ), it moves through the states of the cognate ( $i = 1 \dots 5$ ) or near-cognate branch ( $i = 6 \dots 10$ ), or attains state ( $c|11$ ) upon binding of a non-cognate ternary complex. After translocation to the next codon  $c'$ , the ribosome reaches state ( $c'|0'$ ). With the exception of the binding rates (of cognate, near-, and non-cognate ternary complexes; green, orange and purple arrows), all transition rates are assumed to be codon-independent. Figure previously published in [28].

(PDF)

**S3 Fig. EF-Tu dependences in the 2C-2T system.** A) Normalized concentrations of free EF-Tu molecules (solid lines), free ternary complexes of the more abundant species 1 (dotted lines) and of the less abundant species 2 (dashed lines) as determined by the set of Eqs. (18)–(21) ( $p_1/p_2 = 1$  and  $X_1/X_2$  as indicated; concentrations relative to their value at 500  $\mu$ M of EF-Tu). In the low-concentration regime  $\mathcal{E} < \mathcal{E}^*$ , the free ternary complex concentration of the more abundant species 1 increases roughly linearly with  $\mathcal{E}$  whereas the concentration of the less abundant species 2 remains practically zero up to  $\mathcal{E}^*$ . All parameters as in Fig 3B) in the main text. B) Concentrations of free, aminoacylated (charged) tRNAs and free, de-aminoacylated (uncharged) tRNAs of species 1 and 2, same parameters and corresponding color code as in A). Note that always a substantial fraction of tRNAs is bound to the A, P, and E sites of actively translating ribosomes, see [28] for detailed derivations of the corresponding equations.

(PDF)

**S4 Fig. Impact of codon usage.** A) Overall elongation rate and B) concentrations of free EF-Tu molecules (solid lines), free ternary complexes of the more abundant species 1 (dotted lines) and of the less abundant species 2 (dashed lines) as a function of the concentration of EF-Tu for different codon usages  $p_i$  and tRNA concentrations  $X_i$  ( $i = 1, 2$ ) (see legend). All

other parameters as in Fig 3A) and 3B) in the main text. Vertical solid black lines indicate EF-Tu threshold concentrations as given by Eq (1) in the main text. The same color code is used in A) and B).

(PDF)

**S5 Fig. 2C-2T translation system without near-cognate tRNA incorporation.** A) Overall elongation rate and B) concentrations of free EF-Tu molecules (solid lines), free ternary complexes of the more abundant species 1 (dotted lines) and of the less abundant species 2 (dashed lines) as a function of the concentration of EF-Tu. Here, the incorporation of near-cognate tRNAs is suppressed ( $\omega_{9,10} = 0$ , see S2 Fig). All other parameters as in Fig 3A) and 3B) in the main text.

(PDF)

## Acknowledgments

The author thanks Tomoaki Matsuura and Yoshihiro Shimizu for providing an extended version of the PURE system simulator. Furthermore, the author would like to thank Reinhard Lipowsky for constructive discussions; and Reinhard Lipowsky and Nadin Haase for critical comments on the manuscript.

## Author Contributions

**Conceptualization:** Sophia Rudolf.

**Data curation:** Sophia Rudolf.

**Formal analysis:** Sophia Rudolf.

**Investigation:** Sophia Rudolf.

**Methodology:** Sophia Rudolf.

**Project administration:** Sophia Rudolf.

**Software:** Sophia Rudolf.

**Supervision:** Sophia Rudolf.

**Validation:** Sophia Rudolf.

**Visualization:** Sophia Rudolf.

**Writing – original draft:** Sophia Rudolf.

**Writing – review & editing:** Sophia Rudolf.

## References

1. Frank J, Gonzalez RL. Structure and Dynamics of a Processive Brownian Motor: The Translating Ribosome. *Annual Review of Biochemistry*. 2010; 79(1):381–412. <https://doi.org/10.1146/annurev-biochem-060408-173330> PMID: 20235828
2. Rodnina MV. Translation in Prokaryotes. *Cold Spring Harbor Perspectives in Biology*. 2018;.
3. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. *Nature Reviews Microbiology*. 2013; 12:35 EP –. <https://doi.org/10.1038/nrmicro3155>
4. Lin J, Zhou D, Steitz TA, Polikanov YS, Gagnon MG. Ribosome-Targeting Antibiotics: Modes of Action, Mechanisms of Resistance, and Implications for Drug Design. *Annual Review of Biochemistry*. 2018; 87(1):451–478. <https://doi.org/10.1146/annurev-biochem-062917-011942> PMID: 29570352

5. Parmeggiani A, Nissen P. Elongation factor Tu-targeted antibiotics: Four different structures, two mechanisms of action. *FEBS Letters*. 2006; 580(19):4576–4581. <https://doi.org/10.1016/j.febslet.2006.07.039> PMID: 16876786
6. Wolf H, Chinali G, Parmeggiani A. Mechanism of the Inhibition of Protein Synthesis by Kirromycin. *European Journal of Biochemistry*. 1977; 75(1):67–75. <https://doi.org/10.1111/j.1432-1033.1977.tb11504.x> PMID: 324765
7. Zuurmond AM, Olsthoorn-Tieleman LN, de Graaf JM, Parmeggiani A, Kraal B. Mutant EF-Tu species reveal novel features of the enacyloxin IIa inhibition mechanism on the ribosome. *Journal of Molecular Biology*. 1999; 294(3):627–637. <https://doi.org/10.1006/jmbi.1999.3296> PMID: 10610785
8. Fischer N, Neumann P, Konevega AL, Bock LV, Ficner R, Rodnina MV, et al. Structure of the E. coli ribosome-EF-Tu complex at <3 Å resolution by C<sub>s</sub>-corrected cryo-EM. *Nature*. 2015; 520:567 EP –. <https://doi.org/10.1038/nature14275> PMID: 25707802
9. Prezioso SM, Brown NE, Goldberg JB. Efmamycins: inhibitors of elongation factor-Tu. *Molecular Microbiology*. 2017; 106(1):22–34. <https://doi.org/10.1111/mmi.13750> PMID: 28710887
10. Lewis K. Persister Cells. *Annual Review of Microbiology*. 2010; 64(1):357–372. <https://doi.org/10.1146/annurev.micro.112408.134306> PMID: 20528688
11. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial Persistence as a Phenotypic Switch. *Science*. 2004; 305(5690):1622–1625. <https://doi.org/10.1126/science.1099390> PMID: 15308767
12. Page R, Peti W. Toxin-antitoxin systems in bacterial growth arrest and persistence. *Nature Chemical Biology*. 2016; 12(4):208–214. <https://doi.org/10.1038/nchembio.2044> PMID: 26991085
13. Rotem E, Loinger A, Ronin I, Levin-Reisman I, Gabay C, Shoshitaishvili N, et al. Regulation of phenotypic variability by a threshold-based mechanism underlies bacterial persistence. *Proceedings of the National Academy of Sciences*. 2010; 107(28):12541–12546. <https://doi.org/10.1073/pnas.1004333107>
14. Hazan R, Sat B, Reches M, Engelberg-Kulka H. Postsegregational Killing Mediated by the P1 Phage “Addiction Module” phd-doc Requires the Escherichia coli Programmed Cell Death System mazEF. *Journal of Bacteriology*. 2001; 183(6):2046–2050. <https://doi.org/10.1128/JB.183.6.2046-2050.2001> PMID: 11222604
15. Cruz JW, Woychik NA. Teaching Fido New ModiFICation Tricks. *PLoS Pathogens*. 2014; 10(9): e1004349. <https://doi.org/10.1371/journal.ppat.1004349> PMID: 25255332
16. Cruz JW, Rothenbacher FP, Maehigashi T, Lane WS, Dunham CM, Woychik NA. Doc Toxin Is a Kinase That Inactivates Elongation Factor Tu. *Journal of Biological Chemistry*. 2014; 289(11):7788–7798. <https://doi.org/10.1074/jbc.M113.544429> PMID: 24448800
17. Castro-Roa D, Garcia-Pino Abel, De Gieter S, van Nuland NAJ, Loris R, Zenkin N. The Fic protein Doc uses an inverted substrate to phosphorylate and inactivate EF-Tu. *Nature Chemical Biology*. 2013; 9(12):811–817. <https://doi.org/10.1038/nchembio.1364> PMID: 24141193
18. Alexander C, Bilgin N, Lindschau C, Mesters JR, Kraal B, Hilgenfeld R, et al. Phosphorylation of Elongation Factor Tu Prevents Ternary Complex Formation. *Journal of Biological Chemistry*. 1995; 270(24):14541–14547. <https://doi.org/10.1074/jbc.270.24.14541> PMID: 7782317
19. Klumpp S, Scott M, Pedersen S, Hwa T. Molecular crowding limits translation and cell growth. *Proceedings of the National Academy of Sciences*. 2013; 110(42):16754–16759. <https://doi.org/10.1073/pnas.1310377110>
20. Selva E, Beretta G, Montanini N, Saddler GS, Gastaldo L, Ferrari P, et al. Antibiotic GE2270 A: A Novel Inhibitor Of Bacterial Protein Synthesis. *The Journal of Antibiotics*. 1991; 44(7):693–701. <https://doi.org/10.7164/antibiotics.44.693> PMID: 1908853
21. Parmeggiani A, Krab IM, Okamura S, Nielsen RC, Nyborg J, Nissen P. Structural Basis of the Action of Pulvomycin and GE2270 A on Elongation Factor Tu. *Biochemistry*. 2006; 45(22):6846–6857. <https://doi.org/10.1021/bi0525122> PMID: 16734421
22. LaMarche MJ, Leeds JA, Amaral A, Brewer JT, Bushell SM, Deng G, et al. Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection. *Journal of Medicinal Chemistry*. 2012; 55(5):2376–2387. <https://doi.org/10.1021/jm201685h> PMID: 22315981
23. Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, et al. Multicenter, Randomized Clinical Trial To Compare the Safety and Efficacy of LFF571 and Vancomycin for Clostridium difficile Infections. *Antimicrobial Agents and Chemotherapy*. 2015; 59(3):1435–1440. <https://doi.org/10.1128/AAC.04251-14> PMID: 25534727
24. Gzyl KE, Wieden HJ. Tetracycline does not directly inhibit the function of bacterial elongation factor Tu. *PLOS ONE*. 2017; 12(5):e0178523–. <https://doi.org/10.1371/journal.pone.0178523> PMID: 28552981
25. Pereira SFF, Gonzalez RL, Dworkin J. Protein synthesis during cellular quiescence is inhibited by phosphorylation of a translational elongation factor. *Proceedings of the National Academy of Sciences*. 2015; 112(25):E3274–E3281. <https://doi.org/10.1073/pnas.1505297112>

26. Parmeggiani A, Krab IM, Watanabe T, Nielsen RC, Dahlberg C, Nyborg J, et al. Enacyloxin Ila Pinpoints a Binding Pocket of Elongation Factor Tu for Development of Novel Antibiotics. *Journal of Biological Chemistry*. 2006; 281(5):2893–2900. <https://doi.org/10.1074/jbc.M505951200> PMID: 16257965
27. Rudorf S, Thommen M, Rodnina MV, Lipowsky R. Deducing the Kinetics of Protein Synthesis *in vivo* from the Transition Rates Measured *in vitro*. *PLoS Computational Biology*. 2014; 10(10):e1003909. <https://doi.org/10.1371/journal.pcbi.1003909> PMID: 25358034
28. Rudorf S, Lipowsky R. Protein Synthesis in *E. coli*: Dependence of Codon-Specific Elongation on tRNA Concentration and Codon Usage. *PLoS ONE*. 2015; 10(8):1–22. <https://doi.org/10.1371/journal.pone.0134994>
29. Mustafi M, Weisshaar JC. Simultaneous Binding of Multiple EF-Tu Copies to Translating Ribosomes in Live *Escherichia coli*. *mBio*. 2018; 9(1). <https://doi.org/10.1128/mBio.02143-17> PMID: 29339430
30. Meide PHVD, Vijgenboom E, Dicke M, Bosch L. Regulation of the expression of *tufA* and *tufB*, the two genes coding for the elongation factor EF-Tu in *Escherichia coli*. *FEBS Letters*. 1982; 139(2):325–330. [https://doi.org/10.1016/0014-5793\(82\)80881-8](https://doi.org/10.1016/0014-5793(82)80881-8) PMID: 7042394
31. Matsuura T, Tanimura N, Hosoda K, Yomo T, Shimizu Y. Reaction dynamics analysis of a reconstituted *Escherichia coli* protein translation system by computational modeling. *Proceedings of the National Academy of Sciences*. 2017;. <https://doi.org/10.1073/pnas.1615351114>
32. Neidhardt FC, Bloch PL, Pedersen S, Reeh S. Chemical Measurement of Steady-state Levels of 10 Aminoacyl Transfer Ribonucleic-acid Synthetases In *Escherichia coli*. *Journal of Bacteriology*. 1977; 129(1):378–387. PMID: 318645
33. NießA, Failmezger J, Kuschel M, Siemann-Herzberg M, Takors R. Experimentally Validated Model Enables Debottlenecking of *in Vitro* Protein Synthesis and Identifies a Control Shift under *in Vivo* Conditions. *ACS Synthetic Biology*. 2017; 6(10):1913–1921. <https://doi.org/10.1021/acssynbio.7b00117>
34. Elf J, Nilsson D, Tenson T, Ehrenberg M. Selective charging of tRNA isoacceptors explains patterns of codon usage. *Science*. 2003; 300:1718–1722. <https://doi.org/10.1126/science.1083811> PMID: 12805541
35. Dong H, Nilsson L, Kurland CG. Co-variation of tRNA abundance and codon usage in *Escherichia coli* at different growth rates. *Journal of Molecular Biology*. 1996; 260(5):649–663. <https://doi.org/10.1006/jmbi.1996.0428> PMID: 8709146
36. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, Nishikawa K, et al. Cell-free translation reconstituted with purified components. *Nature Biotechnology*. 2001; 19:751 EP –. <https://doi.org/10.1038/90802> PMID: 11479568
37. Škrtić M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, et al. Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia. *Cancer Cell*. 2011; 20(5):674–688. <https://doi.org/10.1016/j.ccr.2011.10.015> PMID: 22094260
38. Jakobsson ME, Matecki JM, Halabelian L, Nilges BS, Pinto R, Kudithipudi S, et al. The dual methyltransferase METTL13 targets N terminus and Lys55 of eEF1A and modulates codon-specific translation rates. *Nature Communications*. 2018; 9(1):3411. <https://doi.org/10.1038/s41467-018-05646-y> PMID: 30143613
39. Valente L, Tiranti V, Marsano R, Malfatti E, Fernandez-Vizarra E, Donnini C, et al. Infantile Encephalopathy and Defective Mitochondrial DNA Translation in Patients with Mutations of Mitochondrial Elongation Factors EFG1 and EFTu. *The American Journal of Human Genetics*. 2007; 80(1):44–58. <https://doi.org/10.1086/510559> PMID: 17160893
40. Valente L, Shigi N, Suzuki T, Zeviani M. The R336Q mutation in human mitochondrial EFTu prevents the formation of an active mt-EFTu-GTP-aa-tRNA ternary complex. *Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease*. 2009; 1792(8):791–795. <https://doi.org/10.1016/j.bbadis.2009.06.002>
41. Bhatt R, Chudaev M, Mandeck W, Goldman E. Engineered EF-Tu and tRNA-Based FRET Screening Assay to Find Inhibitors of Protein Synthesis in Bacteria. *ASSAY and Drug Development Technologies*. 2018; 16(4):212–221. <https://doi.org/10.1089/adt.2018.843> PMID: 29870274
42. Liang ST, Xu YC, Dennis PP, Bremer H. mRNA composition and control of bacterial gene expression. *Journal of Bacteriology*. 2000; 182(11):3037–3044. <https://doi.org/10.1128/jb.182.11.3037-3044.2000> PMID: 10809680